Add to ORKGIntroduction: The effect of disease-modifying therapies (DMT) on vaccine responses is largely unknown. Understanding the development of protective immunity is of paramount importance to fight the COVID-19 pandemic. Objective: To characterise humoral immunity after mRNA-COVID-19 vaccination of people with multiple sclerosis (pwMS). Methods: All pwMS in Norway fully vaccinated against SARS-CoV-2 were invited to a national screening study. Humoral immunity was assessed by measuring anti-SARS-CoV-2 SPIKE RBD IgG response 3–12 weeks after full vaccination, and compared with healthy subjects. Results: 528 pwMS and 627 healthy subjects were included. Reduced humoral immunity (anti-SARS-CoV-2 IgG <70 arbitrary units) was present in 82% and 80% o...
Background: COVID-19 vaccines are recommended for people with multiple sclerosis (pwMS). Adequate hu...
Background: Few studies investigated the immune response to SARS-CoV-2 vaccine in patients with mult...
Background: In patients with Multiple Sclerosis (pwMS) disease-modifying therapies (DMTs) affects im...
Introduction The effect of disease-modifying therapies (DMT) on vaccine responses is largely unknown...
Introduction The effect of disease-modifying therapies (DMT) on vaccine responses is largely unknown...
Introduction: During the COVID-19 pandemic, certain disease modifying therapies (DMTs) used in multi...
Objectives: Vaccination against COVID-19 is highly recommended to patients affected by multiple scle...
Background: Vaccination campaign to contrast the spread of severe acute respiratory syndrome coronav...
OBJECTIVE: To analyze the humoral response after COVID-19 vaccination in patients with multiple scle...
Introduction: Real-world clinical data suggest an attenuated short-term humoral response to SARS-CoV...
BackgroundVaccination campaign to contrast the spread of severe acute respiratory syndrome coronavir...
Background: COVID-19 vaccines are recommended for people with multiple sclerosis (pwMS). Adequate hu...
Background: Few studies investigated the immune response to SARS-CoV-2 vaccine in patients with mult...
Background: In patients with Multiple Sclerosis (pwMS) disease-modifying therapies (DMTs) affects im...
Introduction The effect of disease-modifying therapies (DMT) on vaccine responses is largely unknown...
Introduction The effect of disease-modifying therapies (DMT) on vaccine responses is largely unknown...
Introduction: During the COVID-19 pandemic, certain disease modifying therapies (DMTs) used in multi...
Objectives: Vaccination against COVID-19 is highly recommended to patients affected by multiple scle...
Background: Vaccination campaign to contrast the spread of severe acute respiratory syndrome coronav...
OBJECTIVE: To analyze the humoral response after COVID-19 vaccination in patients with multiple scle...
Introduction: Real-world clinical data suggest an attenuated short-term humoral response to SARS-CoV...
BackgroundVaccination campaign to contrast the spread of severe acute respiratory syndrome coronavir...
Background: COVID-19 vaccines are recommended for people with multiple sclerosis (pwMS). Adequate hu...
Background: Few studies investigated the immune response to SARS-CoV-2 vaccine in patients with mult...
Background: In patients with Multiple Sclerosis (pwMS) disease-modifying therapies (DMTs) affects im...